Tweet mmmmM…my favourite subject….Yep my Bad…I don’t know the back end of a flagelleum from the front end…So I will do like every respecting cheat and use AI rather than reading and ask it to tell me what the important bacteria in MS are. Here…
The post People with MS experience pain more frequently than the general population, research reveals appeared first on MS Australia. Source: www.msaustralia.org.au
Tweet Higgins V, Parker ML, Ahmed B, Bhayana V, Booth RA, Chen Y, Collier C, Freedman MS, Gagné M, Ismail OZ, Gifford JL, Macri J, Moore CS, Newbigging A, Olayinka L, Poliakov I, Rodriguez-Capote K, Schneider R, Thebault S, Yang L, Beriault DR. Best practice…
Tweet Alroughani R, Ahmed SF. Treatment outcomes of high-efficacy disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A longitudinal observational study. Mult Scler Relat Disord. 2026 Jan 19;108:107024. doi: 10.1016/j.msard.2026.107024. Epub ahead of print. Background: The evolution of high-efficacy disease-modifying therapies (HE-DMTs) has significantly shifted the…
Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label…
By Stacie Prada Lately, I’ve been pausing periodically throughout each day to ask myself, “How do I want to show up today?” It only takes a moment, just enough time for a brief inhale and exhale. It allows me to … Continue reading → Source:…
Tweet In the UK people have a real issue with non-human primate research and there is essentially no MS related work ongoing in the UK. You know we love our furry friends and in the 1980s when I worked in a place where people worked…
Several (OK, many) years ago, I was having lunch with a group of fellow Green Berets when a news story appeared on the TV. The report covered a recent tragedy, and during an interview with a survivor, it was mentioned that one of the victims…
The University of California San Francisco (UCSF) is teaming up with Nektar Therapeutics to study the potential of NKTR-0165, an experimental antibody that activates the tumor necrosis factor receptor type 2 (TNFR2), to treat multiple sclerosis (MS). UCSF neurologist Stephen L. Hauser, MD, and his…
Breastfeeding for longer during infancy may delay the onset of multiple sclerosis (MS) and slow its progression for people who later develop the disease, according to a study from Turkey. Researchers found that adults with MS who had been breastfed for more than six months…